Other languages Takeda Pharmaceutical Company Limited Wiener Boerse

Equities

TKD

JP3463000004

Real-time Estimate Tradegate Other stock markets 01:28:00 20/06/2024 am IST			5-day change	1st Jan Change
23.52 ^EUR	-4.29%		-1.09%	-4.80%

18/06	Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	MT
18/06	Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	10:56pm
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	08:14pm
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	01:55pm
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	18/06
Sector Update: Health Care Stocks Decline Premarket Monday	17/06
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	17/06
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	17/06
Takeda's seizure drug fails to meet main goal in late-stage studies	17/06
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	17/06
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	17/06
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	14/06
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	14/06
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema	06/06
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	06/06
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints	03/06
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial	03/06
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861	03/06
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	01/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited Wiener Boerse

Equities

TKD

JP3463000004

Other languages

Filters